05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
20:05 , Nov 26, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Peptides; polymers An amphiphilic dendrimer-peptide construct could be used for tumor-targeted delivery of siRNA therapies. The construct has four components: an amphiphilic dendrimer complex for loading with siRNA cargo; a peptide composed of repeating...
20:01 , Nov 2, 2018 |  BC Week In Review  |  Company News

Takeda proposes divestment of Shire GI candidate, announces loans

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it proposed to the European Commission a potential divestment of Crohn’s disease and ulcerative colitis candidate SHP647 once it completes its acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG). The move...
18:16 , Sep 28, 2018 |  BioCentury  |  Finance

Morphic reloads

With Morphic Therapeutic’s second integrin program running ahead of schedule, the company has raised an $80 million series B round to sustain its current development pace. Existing investor Omega Funds and new investor Novo Holdings...
13:56 , Sep 25, 2018 |  BC Extra  |  Financial News

Morphic's $80M round paves way for integrin clinical studies

Morphic Therapeutic (Waltham, Mass.) raised $80 million in a series B round led by existing investor Omega Funds and new investor Novo Holdings A/S (Hellerup, Denmark). New investors Invus and EcoR1 Capital, and existing investors...
03:14 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

New Phase IIb analyses support further development of Protagonist's UC candidate

Protagonist Therapeutics Inc. (NASDAQ:PTGX) said new analyses from the discontinued Phase IIb PROPEL trial of PTG-100 to treat moderate to severe ulcerative colitis showed that the initial findings by an IDMC were "an unfortunate consequence...
17:00 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Takeda's subcutaneous Entyvio meets in Phase III for maintenance therapy of ulcerative colitis

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said subcutaneous Entyvio vedolizumab as maintenance therapy met the primary endpoint vs. placebo in the Phase III VISIBLE 1 trial to treat ulcerative colitis in patients who achieved a clinical...
23:16 , Jul 20, 2018 |  BC Extra  |  Preclinical News

PI3K inhibitors may block cancer's access to CNS

Researchers from Duke University, Gilead Sciences Inc. (NASDAQ:GILD) and colleagues suggested that acute lymphoblastic leukemia (ALL) cells metastasize to the CNS by traveling along vessels rich in laminin, a protein associated with motility of neuronal...
16:35 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Fibrotic disease company Pliant raises $62M series B

Fibrosis play Pliant Therapeutics Inc. (Redwood City, Calif.) raised $62 million on July 16 in an untranched series B round led by Cowen Healthcare Investments. Fellow new investors Eventide Asset Management, Schroder Adveq, Menlo Ventures,...
17:45 , Jul 18, 2018 |  BioCentury  |  Finance

Fibrosis firsts

Pliant Therapeutics Inc.’s preclinical models and discovery technology prompted Cowen Healthcare Investments and Menlo Ventures to choose the company as their first fibrosis investments. Cowen led Pliant’s untranched $62 million series B round on Monday,...